» Authors » Hagen F Kennecke

Hagen F Kennecke

Explore the profile of Hagen F Kennecke including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 1117
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Morris V, Kennedy E, Amin M, Aranha O, Benson 3rd A, Dorth J, et al.
J Clin Oncol . 2024 Dec; 43(5):605-615. PMID: 39680825
Purpose: To provide evidence-based guidance for clinicians who treat patients with stage I-III anal cancer. Methods: A systematic review of the literature conducted by the Minnesota Evidence-based Practice Center provided...
2.
Krishnan T, Solar Vasconcelos J, Titmuss E, Vanner R, Schaeffer D, Karsan A, et al.
Cancer Res Commun . 2024 Dec; 5(1):66-73. PMID: 39636207
Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. CHIP is a common incidental finding in cfDNA, and its prevalence increases with age. This study builds on...
3.
Ma L, Titmuss E, Loree J, Jonker D, Kennecke H, Berry S, et al.
J Immunother Cancer . 2024 Dec; 12(12. PMID: 39631846
Background: Nutritional stress is a mechanism that allows tumor cells to evade the immune system. Arginine (ARG), an amino acid involved in immunomodulation, aids in regulating T-lymphocyte cell activity and...
4.
Wu F, Topham J, OCallaghan C, Feilotter H, Kennecke H, Drusbosky L, et al.
JCO Precis Oncol . 2024 Aug; 8:e2400031. PMID: 39178370
Purpose: In metastatic colorectal cancer (mCRC), mutations drive resistance to anti-epidermal growth factor receptor antibodies. It is unclear whether mutations ever become clonally undetectable. Methods: CO.26 was a phase II...
5.
Scott A, Kennedy E, Berlin J, Brown G, Chalabi M, Cho M, et al.
J Clin Oncol . 2024 Aug; 42(28):3355-3375. PMID: 39116386
. .PURPOSETo provide evidence-based guidance for clinicians who treat patients with locally advanced rectal cancer.METHODSA systematic review of the literature published from 2013 to 2023 was conducted to identify relevant...
6.
Loree J, Titmuss E, Topham J, Kennecke H, Feilotter H, Virk S, et al.
Clin Cancer Res . 2024 May; 30(15):3189-3199. PMID: 38727700
Purpose: Tissue-derived tumor mutation burden (TMB) of ≥10 mutations/Mb is a histology-agnostic biomarker for the immune checkpoint inhibitor (ICI) pembrolizumab. However, the dataset in which this was validated lacked colorectal...
7.
Chen E, Loree J, Titmuss E, Jonker D, Kennecke H, Berry S, et al.
JAMA Netw Open . 2023 Dec; 6(12):e2346094. PMID: 38051531
Importance: Immune checkpoint inhibitors (ICIs) have limited activity in microsatellite-stable (MSS) or mismatch repair-proficient (pMMR) colorectal cancer. Recent findings suggest the efficacy of ICIs may be modulated by the presence...
8.
Halfdanarson T, Mallak N, Paulson S, Chandrasekharan C, Natwa M, Kendi A, et al.
Cancers (Basel) . 2023 Oct; 15(19). PMID: 37835530
Radioligand therapy (RLT) with [Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent...
9.
Judge S, Ghalambor T, Cavnar M, Lidsky M, Merkow R, Cho M, et al.
Ann Surg Oncol . 2023 Sep; 30(12):7362-7370. PMID: 37702903
Background: An increasing number of hepatic artery infusion (HAI) programs have been established worldwide. Practice patterns for this complex therapy across these programs have not been reported. This survey aimed...
10.
Kennecke H, Auer R, Cho M, Dasari N, Davies-Venn C, Eng C, et al.
J Natl Cancer Inst . 2023 Aug; 115(12):1457-1464. PMID: 37535679
The optimal management of locally advanced rectal cancer is rapidly evolving. The National Cancer Institute Rectal-Anal Task Force convened an expert panel to develop consensus on the design of future...